Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

[1]  T. Mikkelsen,et al.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.

[2]  A. Melcher,et al.  Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. , 2016, Neuro-oncology.

[3]  B. Leuchs,et al.  Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. , 2016, Journal of virological methods.

[4]  J. Markert,et al.  To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses , 2016, Viruses.

[5]  G. Reifenberger,et al.  Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. , 2015, Neuro-oncology.

[6]  J. Rommelaere,et al.  Double-faceted mechanism of parvoviral oncosuppression. , 2015, Current opinion in virology.

[7]  B. Leuchs,et al.  Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. , 2015, Comparative medicine.

[8]  B. Leuchs,et al.  Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. , 2015, Comparative medicine.

[9]  P. Tattersall,et al.  Parvoviruses: Small Does Not Mean Simple. , 2014, Annual review of virology.

[10]  H. Urbach,et al.  O10.04THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE , 2014 .

[11]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[12]  E. Chiocca,et al.  Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  R. Weichselbaum,et al.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  R. Cattaneo,et al.  New viruses for cancer therapy: meeting clinical needs , 2013, Nature Reviews Microbiology.

[15]  Christina Appin,et al.  Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class , 2013, Clinical Cancer Research.

[16]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[17]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[18]  A. Marchini,et al.  Molecular Pathways: Rodent Parvoviruses—Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment , 2012, Clinical Cancer Research.

[19]  Y. De Launoit,et al.  Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus , 2012, PloS one.

[20]  A. Ernst,et al.  Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. , 2012, Neuro-oncology.

[21]  M. von Knebel Doeberitz,et al.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.

[22]  Susan M. Chang,et al.  Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.

[23]  D. Mouginot,et al.  Combined fluorescent in situ hybridization and immunofluorescence: Limiting factors and a substitution strategy for slide-mounted tissue sections , 2011, Journal of Neuroscience Methods.

[24]  T. Giese,et al.  Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent , 2010, Cancer biology & therapy.

[25]  O. Witt,et al.  Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells , 2010, International journal of cancer.

[26]  C. Sommer,et al.  Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. , 2010, Neuro-oncology.

[27]  J. Rommelaere,et al.  Oncolytic parvoviruses as cancer therapeutics. , 2010, Cytokine & growth factor reviews.

[28]  B. Yoo,et al.  Induction of glioma apoptosis by microglia-secreted molecules: The role of nitric oxide and cathepsin B. , 2009, Biochimica et biophysica acta.

[29]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[30]  B. Thompson,et al.  A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  R. Ortíz-López,et al.  Oncolytic virotherapy. , 2008, Annals of hepatology.

[32]  J. Rommelaere,et al.  Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells , 2007, Journal of Virology.

[33]  J. Buckner,et al.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.

[34]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[35]  J. Olson,et al.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  S. Brown,et al.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.

[37]  A. Silahtaroglu,et al.  FISHing with locked nucleic acids (LNA): evaluation of different LNA/DNA mixmers. , 2003, Molecular and cellular probes.

[38]  J. Pocock,et al.  Microglial secreted cathepsin B induces neuronal apoptosis , 2001, Journal of neurochemistry.

[39]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[40]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[41]  P. Tattersall,et al.  Biochemical Activities of Minute Virus of Mice Nonstructural Protein NS1 Are Modulated In Vitro by the Phosphorylation State of the Polypeptide , 1998, Journal of Virology.

[42]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[44]  P. Tattersall,et al.  Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice , 1983, Journal of virology.

[45]  J. Stamp,et al.  Viral diseases , 1975, Nature.

[46]  J. Sever,et al.  Attempts to isolate H-1 virus from spontaneous human abortions: a negative report. , 1970, Teratology.

[47]  A. Levin,et al.  H-1 Virus Viremia in the Human.∗ , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.